Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
In April 2026, the FDA announced that its Pharmacy Compounding Advisory Committee (PCAC) will meet on July 23 and 24, 2026, to discuss several peptide-related bulk drug substances for possible inclusion on the 503A Bulks List
/sc-assets/prd/practices/e078c756-43b0-4d1b-970d-d061dbd5c29d/tag-1736537230834.png)
It is primarily used as a research tool to explore age-related cellular pathways and compare experimental outcomes across conditions
No Hematopoietic Effect: ARA-290 does not bind to the homodimeric EPO receptor (EPOR/EPOR) responsible for red blood cell production
Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
US$ 24.12
US$ 21.66
US$ 23.07
US$ 27.59
